

Levodopa response and acoustic parameters of prominence marking as well as tongue body movements in patients with Parkinson's disease

Tabea Thies^{1,2}, Richard Dano³, Michael T. Barbe², Doris Mücke¹


Background

- Parkinson's Disease affects non-motor and motor functions
- Slower, smaller and less extended movements of limbs and oral articulators
- The drug 'levodopa' improves gross motor skills [1], but unclear if it also influences speech motor control

Does Levodopa influences speech production?

Method

- 12 Patients with Parkinson's disease
- Rating motor ability using standard assessment [2]
- Speech Recordings with an Electromagnetic Articulograph



Measurements

Levodopa Response

$$\frac{\text{Motor Rating}_{\text{med-ON}} - \text{Motor Rating}_{\text{med-OFF}}}{\text{Motor Rating}_{\text{med-OFF}}} \times 100$$


Intensity



F0




Syllable duration



unaccented accented

higher intensity
longer syllables
rising F0 movements

background < broad focus < contrastive focus




Levodopa Response

- 10 out of 12 patients responded to levodopa intake
- 42.5 % motor improvement
- Levodopa influences speech production – in med-ON:


louder speaking style
faster tongue body movements
in less time

Articulation


Vocalic Gesture Duration (ms)



Displacement (mm)




Peak velocity (mm/s)




Acoustic


Intensity (dB)



Tonal height (st) of F0 movement



Syllable Duration (ms)



Speech Material

- Speech Production Task: Question-Answer-Scenario to elicit different degrees of prominence
- disyllabic target words containing one of five cardinal vowels

Vowel Space



Prominence Marking

- Patients keep prominence relations in the acoustic [3] and articulatory dimension.
- With increasing prominence:
 - prolonged and louder target syllables, higher F0 peaks
 - longer and larger tongue body movements during vowel production

Affiliations: 1University of Cologne, Faculty of Arts and Humanities, IFL Phonetics, Germany; 2University of Cologne, Faculty of Medicine and University Hospital, Department Neurology, Germany; 3University of Cologne, Faculty of Medicine, Institute for Nursing Science, Germany

References: [1] Katzenschlager, R., & Lees, A. J. (2002). Treatment of Parkinson's disease: levodopa as the first choice. *Journal of neurology*, 249(2), ii19-ii24.; [2] Goetz, C. G., & the Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: Scale presentation and clinimetric testing results. *Movement Disorders*, 22, 2129-2170.; [3] Thies, T., Mücke, D., Lowit, A., Kalbe, E., Steffen, J., & Barbe, M. T. (2020). Prominence marking in parkinsonian speech and its correlation with motor performance and cognitive abilities. *Neuropsychologia*, 137, 107306.